ANAPTYSBIO, INC.
Moat Score — AnaptysBio, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | AnaptysBio's proprietary somatic hypermutation-based antibody discovery platform has a proven commercial track record via GSK's Jemperli, giving it validated, hard-to-replicate discovery technology and patent-protected antibody candidates in its pipeline. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage biotech with no owned commercial manufacturing, AnaptysBio has no cost-scale advantage and depends on partners like GSK for commercial-scale production and distribution of any resulting products. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | AnaptysBio does not directly control pricing of Jemperli, which is set by GSK, and its own internal pipeline candidates have no approved product yet, so the company has no current independent pricing power. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in antibody drug discovery or royalty-based biotech licensing; value is determined by clinical data, regulatory approval, and partner commercial execution. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once physicians and payers adopt a treatment regimen, some prescribing inertia develops, but with rosnilimab still in clinical development and Jemperli controlled by GSK, AnaptysBio itself has limited direct switching-cost leverage. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Both the immuno-oncology and autoimmune/inflammatory disease markets are large and support numerous competing therapies and platforms, so AnaptysBio gains little protection from efficient-scale dynamics against much larger, established competitors in each therapeutic area. |